Radius Health, Inc.
RDUS evidence brief
What we can confirm
- BioSniper Score:
- 9.3 / 10
- Lead Asset:
- abaloparatide-sc (Phase 3)
What it means
What to watch
Prepared research question
What matters most for RDUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
abaloparatide-sc (Phase 3)
Next Catalyst
—
Tracking 5 pipeline candidates · 2 clinical trials for Radius Health, Inc..
Run Radius Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Radius Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Radius Health, Inc.'s lead drug candidate?
Radius Health, Inc.'s most advanced tracked candidate is abaloparatide-sc (Phase 3) for males with osteoporosis at high risk for fracture.
What therapeutic areas does Radius Health, Inc. focus on?
Radius Health, Inc. develops therapies across Oncology, Rare Disease, Musculoskeletal, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.